XMAS Special

pelobiotech

PELONEWS

WITH FOCUS ON X-MAS

PELOBiotech Newsletter Dec. 2018

“CFO asks

CEO, “What

happens if we

invest in developing

our people

and then

they leave

us?”

CEO: “What

happens if we

don’t, and they

stay?”

~Peter Baeklund,

Leadership

Coach~

Dear Scientist,

a sincere thank you for your confidence in

us and your interest in our products and services.

Wishing you, your staff and your loved ones

a reflective and restful Christmas season and

a happy and healthy New Year, bringing success

in your personal endeavors and business

ventures.

Yours,

Lothar, Peter and the PELOBiotech-Team

Please note due to the holiday season

our delivery times:

last deliveries

CW 51 (Dec 19, 2018; based upon stock)

No deliveries CW52:

Please contact us in between in urgent

matters, we are here to help.

Content

Delivery Dates

NEW Name: Native

Coat

CoSeedis

Featured Fields




3D

ECM

Cancer


PELONews

One happy

family after

the talk:

John O

Neill (4th

from the

right) next

to Tony

Curro,

Richard

Nguyen (1

left)

We have talked: New Generation of ECM Organotypic ECM

To a talk about applied 3D cell culture PELOBiotech GmbH and its US partner EastRiver BioSolutions

from New York invited to the Sky-Room at the IZB End of November 2018,. Around 30 scientists from

Munich biotech companies, the LMU, the Klinikum rechts der Isar, the Helmholtz Centre and the Hochschule

Munich discussed with

Dr. John O´Neill, CSO East River, the importance of the right physiological environment for cell growth.

Guests came from Switzerland and the University of Dublin, Ireland, Prof. Günther Eissner, too.

In his lecture on Native Organotypic ECM (Extracellular Matrix) for Coatings, Hydrogels and Scaffolds

John made it very clear how the targeted use of native coatings not only proliferates the cells but also

improves the adhesion of the cells. "You have to imagine if your cells are in a room with only brick walls.

It's not very comfortable, is it?", John O´Neill explains the functionality of his organspecific product line

compared to competitors such as Matrigel. Those offer often a cocktail disease-associated physiological

factors such as collagens. This convinced the scientists:

"The future of today's research is clearly moving in the direction of 3D," says one of the talk participants.

"The right environment for the cells is becoming increasingly important in my field," she says. Possible

applications include stem cells, tissue engineering, 3D cell culture and cancer research.

Another participant hopes to receive support for his drug screening project from the novel organoid

ECMs: "International research on pancreas organoid models is still in its infancy anyway.”

CSO John O´Neill also had a delicacy for his audience: "Very soon we will be able to offer ECMs not only

of animated but also of human origin". His colleagues Dr. Richard Nguyen, Business Development, and

EastRiver Board Member Anthony A. Curro were particularly impressed by the IZB: “The event

was a great success for us," said Anthony, who is also CEO the Biotech-company Immplacate: “It's

like old times in New York, Alexandria Biotech Center. The audience, a great campus, great people, great

atmosphere.” They will be back – soon, and then EastRiver has a new name: XYLYX Bio.

Want to know more? Browse www.pelobiotech.com or info@pelobiotech.com


EastRiver BioSolutions is now Xylyx Bio

Our partner East River Bio has rebranded! Recognizing the importance of the native cell microenvironment,

Xylyx Bio, formerly ER Bio, is harnessing the power of tissue-specific extracellular

matrix for both drug discovery and tissue regeneration.

NativeCoat and TissueSpec® ECM substrates represent the complexity of natural extracellular

matrices and thus provide the essential cues that underlie cell function to enable cell models that

are significantly more predictive of human physiology.

Your advantages:




Improved cell attachment

Increased cell viability and proliferation

Enhanced function


Activation of signaling pathways

Formerly...

is now


PELONews

Did you know?

The new 3D

CoSeedis Micro-

Tumour System –

WiDr offers fully validated

protocols and includes

all required components

to successfully

grow tumour cells into

3D spheroids. It is ideally

suited to establish the

3D CoSeedis technology

in your lab and provides

easy-to-follow

SOPs for:

Pic : abc biopply

3D CoSeedis: Valuable 3D Data

in Radiation Therapy Response

A recent publication in Translational Oncology (Vol. 11, No. 6, 2018;

1307 – 1322), has shown the importance of proteome studies in the investigation

of carcinoma responsiveness (pancreatic ductal adenocarcinoma,

PDAC) to chemoradiation. Important evidence was provided by

addressing the radiation resistance of A37-treated MiaPaCa-2 3D cell

aggregates in 3D CoSeedis. The publication is available under:

[10.1016/j.tranon.2018.08.001];

or contact us for further information on 3D CoSeedis and its wide range

of applications.

3D aggregate formation

Maintenance of aggregates

for up to 10

weeks

Harvest of grown

spheroids

The system allows to

monitor tumour growth in

real-time and to accurately

measure growthrelated

effects of treatments.

Furthermore, the system

is fully compatible with

abc biopply’s organoid

histology system.

How to reach us:

If you need any further assistance or if you like what you see, tell us:

PELOBiotech GmbH

Klopferspitz 19 82152 Planegg | Germany

Tel.: +49 89 517286 59 0 | info@pelobiotech.com | www.pelobiotech.com

Dr.Peter Frost HRB 197203

We like your feedback – tell us what you love, don’t like so much and what you would like to get, please.

Just reply Please update your subscription anytime, as we like to comply to the new GDPR guidelines.

More magazines by this user